LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Roche Introduces Digital Health Solutions Under Navify Brand

By LabMedica International staff writers
Posted on 08 Nov 2022
Image: The navify portfolio uses digital solutions, analytics and data science to provide health insights (Photo courtesy of Roche)
Image: The navify portfolio uses digital solutions, analytics and data science to provide health insights (Photo courtesy of Roche)

Roche (Basel, Switzerland) has announced that its digital health portfolio will now be available under the navify brand. The navify digital solutions help providers and patients 'navigate' and 'clarify' a wide range of touchpoints by activating insights that provide evidence on how to optimize operational processes and clinical decision making in healthcare.

Together, navify brings new ways to improve interoperability of digital infrastructure, use advanced analytics to deliver operational excellence, improved workflows, and patient-centric ways of working, and generate advanced medical insights that augment clinical decision support. The portfolio across Roche includes more than 30 digital solutions for labs, hospitals and patients worldwide and many key initiatives to advance digital transformation in healthcare. Several late stage pilots with customers and tech collaborators are underway for digital infrastructure (navify Core Integrator), operational excellence (navify Sample Tracking) and for medical insights (navify Screening for Cervical Cancer, navify Kidney Companion and navify Algorithm Suite).

With navify Marketplace, Roche connects labs and healthcare providers and third-party medtech and other companies to help bring innovations to healthcare. Several startups or companies are involved and more are joining: Smart4Diagnostics, imito (wound.app), decide Clinical Software (glucotab), Glytec, Precordior (CardioSignal), SteadySense (SteadyTemp), Deigma, TestCard, Etheclo, Tracie Healthcare Solutions and Binary Tech. Medial EarlySign, which develops AI-based clinical predictive analytics, is the latest to join, allowing for EarlySign ColonFlag to be accessible to labs and hospitals via the navify platform in the near future.

"Today we are using navify digital solutions, such as algorithms, and data science to deliver insights that are actionable in healthcare, building on three decades of software experience with diagnostics in laboratories," said Moritz Hartmann, Head of Roche Information Solutions. "We are creating open digital ecosystems with labs, hospitals and medtech companies to bring the latest innovations faster to society to better serve patients, and to support clinicians in providing care for patients. These activities support our strategy to deliver insights that drive personalised care."

Related Links:
Roche

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Capillary Blood Collection Tube
IMPROMINI M3

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more